Zacks On Access Pharmaceuticals: MuGard Sales Continued To Grow In 1Q12, Will Keep Current Momentum; Outperform (ACCP)

Zacks On Access Pharmaceuticals: MuGard Sales Continued To Grow In 1Q12 And Will Keep Current Momentum; Outperform (ACCP)

Access Pharmaceuticals (ACCP) is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one FDA-approved product, two products in Phase II clinical development, three products in preclinical development. Several of the company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.

Zacks.com has released a report on Access Pharmaceuticals entitled "MuGard sales continued to grow in 1Q12 and will keep current momentum." Zacks maintains an "Outperform" rating on ACCP but lowers the price target.

Purchase the report online at AlacraStore.com.